

Prof. İBRAHİM YILDIZ

Personal Information

Email: ibrahim.yildiz@acibadem.edu.tr

Web: <https://avesis.acibadem.edu.tr/ibrahim.yildiz>

Education Information

Post Doctorate of Medicine, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , Turkey 2010 - 2013

Expertise In Medicine, Istanbul University, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2002 - 2006

Undergraduate, İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, Turkey 1996 - 2002

Research Areas

Health Sciences

Academic Titles / Tasks

Professor, Acibadem Mehmet Ali Aydınlar University, School Of Medicine, Department Of Medical Sciences, 2022 - Continues

Research Assistant, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , 2010 - 2013

Research Assistant, Istanbul University, Dahili Tıp Bilimleri Bölümü, 2002 - 2006

Courses

Prostate cancer: screening, diagnosis, risk factors, principles of therapy, Undergraduate, 2022 - 2023

Prostate cancer: screening, diagnosis, risk factors, principles of therapy, Undergraduate, 2021 - 2022

Advising Theses

Yıldız İ., Mide kanserinde MSI-H ile MSI-H ekspresyonu sıklığı ve klinikopatolojik parametreler ve sağ kalımla ilişkisi, Expertise In Medicine, Ş.BAHŞİ(Student), 2019

Published journal articles indexed by SCI, SSCI, and AHCI

- Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study**
Tasci E. S., KUTLU Y., ÖLMEZ Ö. F., Mutlu A. U., Gundogdu Y., Seyyar M., Sahin E., ÇABUK D., Majidova N., Ugurlu I., et al.
EXPERT OPINION ON PHARMACOTHERAPY, vol.25, no.4, pp.477-484, 2024 (SCI-Expanded)
- The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable**

hepatocellular carcinoma: A multicenter real-world study from Turkey

AKYILDIZ A., Guven D. C., Ozluk A. A., Ismayilov R., Mutlu E., Unal O. U., YILDIZ İ., Iriagac Y., Turhal S., Akbas S., et al
MEDICINE, vol.102, no.45, 2023 (SCI-Expanded)

- III. **Discrepancy among microsatellite instability detection methodologies in non-colorectal cancer: Report of 3 cases**
Tasci E. S., Yildiz İ., Erdamar S., Ozer L.
WORLD JOURNAL OF CLINICAL CASES, no.13, pp.3105-3113, 2023 (SCI-Expanded)
- IV. **Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm**
Aktas M. K., AYTAÇ E., YILDIZ İ., OZER L.
The Lancet Oncology, vol.24, no.5, 2023 (SCI-Expanded)
- V. **Current trends in perioperative treatment of resectable gastric cancer.**
Yıldız İ., Özer L., Şenocak Taşçı E., Bayoglu İ. V., Aytac E.
World journal of gastrointestinal surgery, vol.15, no.3, pp.323-337, 2023 (SCI-Expanded)
- VI. **Intramural Component of Venous, Lymphatic, and Perineural Invasion in Colon Cancer: A Threat or an Illusion?**
Özer L., Taşçı E. Ş., Mutlu A. U., Piyade B., Ramoğlu N., Ajredini M., Gürleyik D., Çeçen R., Dinçer S. N., Musevitoğlu T., et al.
BALKAN MEDICAL JOURNAL, vol.39, no.6, pp.436-443, 2022 (SCI-Expanded)
- VII. **Tailored total neoadjuvant therapy for locally advanced rectal cancer: One size may not fit for all!**
Ozer L., Yıldız İ., Bayoglu V., Bozkurt M., Esen E., Remzi F. H., Gogenur I., Aytaç E.
COLORECTAL DISEASE, vol.23, no.7, pp.1662-1669, 2021 (SCI-Expanded)
- VIII. **Clinicopathological and Prognostic Significance of MSI Status and PD-L1 Expression in Turkish Patients with Gastric Cancer**
Bahsi S., YILDIZ İ., Erdamar S., Goksel S., Tozun N., AYTAÇ E., Demir G., ER O., BACA B., KARAHASANOĞLU T., et al.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.31, no.4, pp.246-254, 2021 (SCI-Expanded)
- IX. **GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients**
Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., Demirci U., Christopoulos P., ÇİÇİN İ., Basal F. B., et al.
LUNG CANCER, vol.148, pp.48-54, 2020 (SCI-Expanded)
- X. **Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey**
Kilickap S., Demirci U., Bugdayci F., Tural D., KORKMAZ T., PAYDAŞ S., Yilmaz C., TURNA Z. H., Sezer A., Cinkir H. Y., et al.
JOURNAL OF THORACIC ONCOLOGY, no.10, 2019 (SCI-Expanded)
- XI. **PDL-1 expression is poor prognostic factor in gastric carcinomas?**
Erdamar S., Bahsi S., YILDIZ İ.
VIRCHOWS ARCHIV, vol.475, 2019 (SCI-Expanded)
- XII. **Dealing with the gray zones in the management of gastric cancer: The consensus statement of the Istanbul Group**
AYTAÇ E., Aslan F., ÇİÇEK B., Erdamar S., Gurses B., GÜVEN K., Falay O., KARAHASANOĞLU T., Selcukbiricik F., Selek U., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, no.7, pp.584-598, 2019 (SCI-Expanded)
- XIII. **Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy.**
Yildiz İ., Bilici A., Karadurmus N., Ozer L., Tural D., Kaplan M. A., Akman T., Bayoglu I., UYSAL M., Yildiz Y., et al.
Tumori, vol.104, no.6, pp.444-450, 2018 (SCI-Expanded)
- XIV. **Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study**
Bilir C., Yildiz İ., Bilici A., Ucar M., Berk V., Yildiz Y., Yazici O., Imamoglu G. I., Karadurmus N., Pilanci K. N., et al.
CANCER INVESTIGATION, vol.35, no.4, pp.248-255, 2017 (SCI-Expanded)

- XV. **SERUM LEVELS OF OMENTIN-1 IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER: THE IZMIR ONCOLOGY GROUP (IZOG) STUDY**
Yildiz Y., KÜÇÜKZEYBEK Y., ALACACIOĞLU A., Taskaynatan H., YILDIZ İ., Varol U., DEMİR L., Akyol M., Salman T., Oflazoglu U., et al.
ACTA MEDICA MEDITERRANEA, vol.33, no.4, pp.549-555, 2017 (SCI-Expanded)
- XVI. **THE EFFECTS OF ADJUVANT CHEMOTHERAPY ON SERUM ADMA AND ENDOTHELIN-1 LEVELS IN EARLY STAGE BREAST CANCER PATIENTS (IZMIR ONCOLOGY GROUP (IZOG) STUDY**
Akyol M., Kara M., Alacacioglu A., Demir L., ELLİDOKUZ H., Kucukzeybek Y., Yildiz Y., Bayoglu V., Yildiz İ., Salman T., et al.
ACTA MEDICA MEDITERRANEA, vol.33, no.4, pp.557-564, 2017 (SCI-Expanded)
- XVII. **Prognostic value of preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with epithelial ovarian cancer**
Yildiz Y., Kucukzeybek Y., Alacacioglu A., Varol U., Yildiz İ., Akyol M., Kabadayi G., Taskaynatan H., Salman T., Bayoglu V., et al.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.38, no.3, pp.444-448, 2017 (SCI-Expanded)
- XVIII. **Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib**
Keizman D., Sarid D., Lee J. L., Sella A., Gottfried M., Hammers H., Eisenberger M. A., Carducci M. A., Sinibaldi V., Neiman V., et al.
ONCOLOGIST, vol.21, no.10, pp.1212-1217, 2016 (SCI-Expanded)
- XIX. **Current adjuvant treatment modalities for gastric cancer: From history to the future**
Kilic L., Ordu C., Yildiz İ., Sen F., Keskin S., Ciftci R., Pilanci K. N.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, vol.8, no.5, pp.439-449, 2016 (SCI-Expanded)
- XX. **Same Chemotherapy Regimen Leads to Different Myelotoxicity in Different Malignancies: A Comparison of Chemotherapy-Associated Myelotoxicity in Patients With Advanced Ovarian and Non-Small-Cell Lung Cancer**
TAŞ F., YILDIZ İ., Kilic L., Ciftci R., Keskin S., Sen F.
AMERICAN JOURNAL OF THERAPEUTICS, vol.23, no.3, 2016 (SCI-Expanded)
- XXI. **The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma**
ERDEM S., YEGEN G., Telci D., YILDIZ İ., TEFİK T., İŞSEVER H., KILIÇASLAN I., ŞANLI M. Ö.
WORLD JOURNAL OF UROLOGY, vol.33, no.10, pp.1553-1560, 2015 (SCI-Expanded)
- XXII. **Frequency of EGFR Mutation in Nsclc and Its Relationship with Clinicopathological Features: A Multicenter Asmo Trial**
Yuksel S., Kodaz H., Yildiz İ., Odabasi H., Ocak A., Bayoglu I. V., Hacibekiroglu I., Ercelep O., Ekinci A. S., ERDOĞAN B., et al.
JOURNAL OF THORACIC ONCOLOGY, vol.10, no.9, 2015 (SCI-Expanded)
- XXIII. **Sexual satisfaction, anxiety, depression and quality of life among Turkish colorectal cancer patients [Izmir Oncology Group (IZOG) study]**
Akyol M., Ulger E., Alacacioglu A., Kucukzeybek Y., Yildiz Y., Bayoglu V., Gumus Z., Yildiz İ., Salman T., Varol U., et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.45, no.7, pp.657-664, 2015 (SCI-Expanded)
- XXIV. **Quality of life in colorectal cancer patients: an Izmir Oncology Group (IZOG) study.**
Akyol M., Ulger E., Alacacioglu A., Kucukzeybek Y., Bayoglu V., Yildiz Y., Yildiz İ., Salman T., Varol U., Demir L., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.20, no.4, pp.1015-22, 2015 (SCI-Expanded)
- XXV. **Evaluation of c-kit (CD 117) expression as a prognostic factor in testicular germ cell tumors: an Izmir Oncology Group (IZOG) study.**
Salman T., Yildiz E., Yildiz İ., Yavuzer D., Unlu M., Varol U., Akyol M., Yildiz Y., Bayoglu V., Kucukzeybek Y., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.20, no.4, pp.1054-60, 2015 (SCI-Expanded)
- XXVI. **Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers**
Bayoglu I. V., Kucukzeybek B. B., Kucukzeybek Y., Varol U., Yildiz İ., Alacacioglu A., Akyol M., Demir L., Dirican A., Yildiz Y., et al.

BIOMEDICINE & PHARMACOTHERAPY, vol.70, pp.190-195, 2015 (SCI-Expanded)

- XXVII. **Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer.**
Vedat Bayoglu I, Yildiz İ, Varol U, Cokmert S, Kucukzeybek Y, Alacacioglu A, Demir L, Dirican A, Akyol M, Yildiz Y, et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.20, no.2, pp.460-7, 2015 (SCI-Expanded)
- XXVIII. **Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma**
Sen F, Yildiz İ, Odabas H, Tambas M, Kilic L, Karadeniz A, Altun M, Ekenel M, Serilmez M, Duranyildiz D, et al.
TUMOR BIOLOGY, vol.36, no.2, pp.1039-1044, 2015 (SCI-Expanded)
- XXIX. **Adjuvant chemotherapy and prognostic factors in stage II colon cancer - Izmir oncology group study**
Kucukzeybek Y, Dirican A, Demir L, Yildirim S, Akyol M, Yildiz Y, Bayoglu I. V., Alacacioglu A, Varol U, Salman T, et al.
Asian Pacific Journal of Cancer Prevention, vol.16, no.6, pp.2413-2418, 2015 (SCI-Expanded)
- XXX. **D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients**
Kilic L, YILDIZ İ, Sen F. K., Erdem M. G., SERİLMEZ M., Keskin S., Ciftci R., KARABULUT S., Ordu C., DURANYILDIZ H. D., et al.
CANCER BIOMARKERS, vol.15, no.4, pp.405-411, 2015 (SCI-Expanded)
- XXXI. **The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study**
Akyol M., Demir L., Alacacioglu A., ELLİDOKUZ H., Kucukzeybek Y., Yildiz Y., Gumus Z., Bayoglu V., Yildiz İ., Salman T., et al.
CHEMOTHERAPY, vol.61, no.2, pp.57-64, 2015 (SCI-Expanded)
- XXXII. **Cardiac tamponade in a patient treated by sunitinib for metastatic renal cell carcinoma.**
Yildiz İ, Varol U, Sen F, Kilic L.
Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, vol.14, no.7, pp.654-6, 2014 (SCI-Expanded)
- XXXIII. **Clinical significance of serum M30 and M65 levels in patients with breast cancer**
TAŞ F., KARABULUT S., YILDIZ İ., DURANYILDIZ H. D.
BIOMEDICINE & PHARMACOTHERAPY, vol.68, no.8, pp.1135-1140, 2014 (SCI-Expanded)
- XXXIV. **Gastric cancer with diffuse hepatic metastases and complete radiological response to triplet chemotherapy**
Varol U, Alacacioglu A, Yildiz İ, Kucukzeybek Y, Uslu R.
JOURNAL OF BUON, vol.19, no.4, pp.1128-1129, 2014 (SCI-Expanded)
- XXXV. **Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial.**
Yildiz İ, Ekenel M, Akman T, Kocar M, Uysal M, Kanitez M, Varol U, Bayoglu I. V., Tural D, Kaplan M. A., et al.
Anticancer research, vol.34, no.8, pp.4329-34, 2014 (SCI-Expanded)
- XXXVI. **The behavior of Turkish cancer patients in fasting during the holy month of Ramadan.**
TAŞ F., KARABULUT S., Ciftci R., YILDIZ İ., Keskin S., Kilic L., Disci R.
Japanese journal of clinical oncology, vol.44, no.8, pp.705-10, 2014 (SCI-Expanded)
- XXXVII. **High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer.**
Ciftci R, TAŞ F., TILGEN YASASEVER C., Aksit E., KARABULUT S., Sen F., Keskin S., Kilic L., YILDIZ İ., Bozbey H. U., et al.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.35, no.7, pp.6941-8, 2014 (SCI-Expanded)
- XXXVIII. **Sexual satisfaction, anxiety, depression and quality of life in testicular cancer survivors**
Alacacioglu A, Ulger E, Varol U, YAVUZŞEN T, Akyol M, Yildiz Y, Yildiz İ, Bayoglu V, Dirican A, Demir L., et al.
MEDICAL ONCOLOGY, vol.31, no.7, 2014 (SCI-Expanded)
- XXXIX. **Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer**

Varol U, Yildiz İ., Salman T., KARABULUT B., Uslu R.

TUMORI J, vol.100, no.4, pp.370-376, 2014 (SCI-Expanded)

- XL. **Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma?**
Karabulut S., Aksit E., Tas F., Ciftci R., Aydiner A., Yildiz İ., Keskin S., Eralp Y., Yasasever C. T., Vatansever S., et al.
TUMOR BIOLOGY, vol.35, no.5, pp.4323-4329, 2014 (SCI-Expanded)
- XLl. **Survival and prognostic factors in adult patients with recurrent or refractory ewing sarcoma family tumours: a 13-years retrospective study in Turkey.**
Yildiz İ., Sen F., Ekenel M., Darendeliler E., Bavbek S., Agaoglu F., Ozger H., Eralp L., Bilgic B., Basaran M.
In vivo (Athens, Greece), vol.28, no.3, pp.403-9, 2014 (SCI-Expanded)
- XLII. **First-Line Mono-Chemotherapy in Frail Elderly Patients with Metastatic Colorectal Cancer**
Varol U., Dirican A., Yildiz İ., Oktay E., Degirmenci M., Alacacioglu A., Barutca S., KARABULUT B., Uslu R.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.7, pp.3157-3161, 2014 (SCI-Expanded)
- XLIII. **Anticancer Therapy for Breast Cancer Patients with Skin Metastases Refractory to Conventional Treatments**
Varol U., Yildiz İ., Alacacioglu A., Uslu R.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.4, pp.1885-1887, 2014 (SCI-Expanded)
- XLIV. **Quality-of-Life in Turkish Cancer Patients: The Impact of Sociodemographic Characteristics, Medical History, and Management**
Toptas T., Yildiz İ., YILDIZ M., Varol U., Bayoglu I. V., Ozguroglip M.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGISİ, vol.24, no.1, pp.23-29, 2014 (SCI-Expanded)
- XLV. **Depression, Anxiety and Sexual Satisfaction in Breast Cancer Patients and their Partners-Izmir Oncology Group Study**
Alacacioglu A., Ulger E., Varol U., Yildiz İ., Salman T., Bayoglu V., Dirican A., Demir L., Akyol M., Yildiz Y., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.24, pp.10631-10636, 2014 (SCI-Expanded)
- XLVI. **Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer**
Bayoglu I. V., Varol U., Yildiz İ., Muslu U., Alacacioglu A., Kucukzeybek Y., Akyol M., Demir L., Dirican A., Cokmert S., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.17, pp.7119-7123, 2014 (SCI-Expanded)
- XLVII. **Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma**
TAŞ F., KARABULUT S., Bilgin E., Sen F., YILDIZ İ., TAŞTEKİN D., Ciftci R., DURANYILDIZ H. D.
TUMOR BIOLOGY, vol.34, no.6, pp.3529-3536, 2013 (SCI-Expanded)
- XLVIII. **Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma**
Yildiz İ., Sen F., Kilic L., Ekenel M., Ordu C., Kilicaslan I., Darendeliler E., Tunc H. M., Varol U., Bavbek S., et al.
CURRENT ONCOLOGY, vol.20, no.6, 2013 (SCI-Expanded)
- XLIX. **The Role of Surgical Methods in the Treatment of Anorectal Malignant Melanoma (AMM)**
Keskin S., Tas F., Karabulut S., Yildiz İ., Kilic L., Ciftci R., Vatansever S.
ACTA CHIRURGICA BELGICA, vol.113, no.6, pp.429-433, 2013 (SCI-Expanded)
- L. **Performance status of patients is the major prognostic factor at all stages of pancreatic cancer.**
TAŞ F., Sen F., Odabas H., Kilic L., Keskin S., YILDIZ İ.
International journal of clinical oncology, vol.18, no.5, pp.839-46, 2013 (SCI-Expanded)
- LI. **Clinical significance of serum M30 and M65 levels in melanoma**
TAŞ F., KARABULUT S., SERİLMEZ M., YILDIZ İ., Sen F., Ciftci R., DURANYILDIZ H. D.
MELANOMA RESEARCH, vol.23, no.5, pp.390-395, 2013 (SCI-Expanded)
- LII. **Serum M65 as a biomarker for metastatic renal cell carcinoma.**
YILDIZ İ., Sen F., Kilic L., Keskin S., DURANYILDIZ H. D., Bilgin E., Disci R., EKENEL M., Darendeliler E., Bavbek S., et al.
Clinical genitourinary cancer, vol.11, no.3, pp.290-6, 2013 (SCI-Expanded)
- LIII. **A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis**

for epithelial ovarian cancer

Yildiz İ., Tas F., Kilic L., Sen F., Saip P., Eralp Y., Keskin S., Karabulut S., Ciftci R., Serilmez M., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.72, no.2, pp.437-444, 2013 (SCI-Expanded)

- LIV. **Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib.**
Sen F., Yildiz İ., Başaran M., Ekenel M., Oz F., Kilic L., Toz B., Gurdal A., Camlica H., Bavbek S., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.18, no.3, pp.775-81, 2013 (SCI-Expanded)
- LV. **Biweekly triplet chemotherapy with gemcitabine, cisplatin and vinorelbine for advanced chemotherapy naive non-small cell lung cancer**
Keskin S., TAŞ F., EKENEL M., Kilic L., Sen F., YILDIZ İ., KARABULUT S., Ciftci R., VATANSEVER S.
TUMORI, vol.99, no.4, pp.463-468, 2013 (SCI-Expanded)
- LVI. **Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC).**
Keskin S., YILDIZ İ., AYDOĞMUŞ ŞEN F., AYDOĞAN F., Kilic L., EKENEL M., Saglam S., ŞAKAR B., Disci R., Aykan F.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol.15, no.5, pp.403-8, 2013 (SCI-Expanded)
- LVII. **Patterns of Complementary and Alternative Medicine Use among Turkish Cancer Patients**
YILDIZ İ., Ozguroglu M., TOPTAŞ T., TURNA Z. H., Sen F., YILDIZ M.
JOURNAL OF PALLIATIVE MEDICINE, vol.16, no.4, pp.383-390, 2013 (SCI-Expanded)
- LVIII. **Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients.**
Aydiner A., Kilic L., Yildiz İ., Keskin S., Sen F., Kucucuk S., Karanlik H., Muslumanoglu M., Igci A.
Medical oncology (Northwood, London, England), vol.30, no.1, pp.354, 2013 (SCI-Expanded)
- LIX. **Clinical and prognostic significance of coagulation assays in advanced epithelial ovarian cancer.**
TAŞ F., Kilic L., Bilgin E., Keskin S., Sen F., Ciftci R., YILDIZ İ., Yasasever V.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, vol.23, no.2, pp.276-81, 2013 (SCI-Expanded)
- LX. **Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy.**
Aykan N. F., Yildiz İ., Sen F., Kilic L., Keskin S., Ciftci R., Karabulut S., Sakar B., Disci R.
Medical oncology (Northwood, London, England), vol.30, no.3, pp.679, 2013 (SCI-Expanded)
- LXI. **Clinical Outcomes and Prognostic Factors Associated with the Response to Erlotinib in Non-Small-Cell Lung Cancer Patients with Unknown EGFR Mutational Status**
Aydiner A., Yildiz İ., Seyidova A.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.5, pp.3255-3261, 2013 (SCI-Expanded)
- LXII. **Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients?**
Kilic L., Ordu C., EKENEL M., YILDIZ İ., Keskin S., Sen F., Gural Z., Asoglu O., KIZIR A., Aykan F.
Medical oncology (Northwood, London, England), vol.30, no.3, pp.660, 2013 (SCI-Expanded)
- LXIII. **Clinical and prognostic significance of coagulation assays in melanoma.**
TAŞ F., Ciftci R., Kilic L., Bilgin E., Keskin S., Sen F., YILDIZ İ., Yasasever V.
Melanoma research, vol.22, no.5, pp.368-75, 2012 (SCI-Expanded)
- LXIV. **Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.**
Yildiz İ., Sen F., Basaran M., Ekenel M., Agaoglu F., Darendeliler E., Tunc H. M., Ozcan F., Bavbek S.
Japanese journal of clinical oncology, vol.41, no.12, pp.1380-7, 2011 (SCI-Expanded)
- LXV. **Triplet chemotherapy combination with gemcitabine, cisplatin, and docetaxel in patients with chemotherapy-naive advanced non-small cell lung cancer**
TAŞ F., Sen F., Guney N., Yildiz İ., Camlica H., Keskin S., Kilic L.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- LXVI. **Frequency of cardiovascular events in patients with metastatic renal cell carcinoma under sunitinib treatment.**

- Yildiz İ., Sen F., BAŞARAN M., Bavbek S. E.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- LXVII. **Impaired coronary flow reserve in patients with metastatic cancer treated with sunitinib.**
Sen F., Yildiz İ., Oflaz H., Oz F., Kilic L., Gurdal A., BAŞARAN M., Bavbek S. E.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- LXVIII. **Triplet chemotherapy combination with gemcitabine, cisplatin, and docetaxel in patients with chemotherapy-naive advanced non-small cell lung cancer**
TAŞ F., Sen F., Guney N., Yildiz İ., Camlica H., Keskin S., Kilic L.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- LXIX. **Noncutaneous melanoma have distinct features from each other and cutaneous melanoma.**
TAŞ F., Keskin S., Karadeniz A., Dagoglu N., Sen F., Kilic L., YILDIZ İ.
Oncology, vol.81, no.5-6, pp.353-8, 2011 (SCI-Expanded)
- LXX. **Optic disc and choroidal metastasis from sporadic medullary thyroid carcinoma: case report and review of the literature.**
Yildiz İ., Sen F., Tuncer S., Kilic L., Basaran M., Bavbek S.
Onkologie, vol.34, no.11, pp.630-3, 2011 (SCI-Expanded)
- LXXI. **An unusual case of recurrent non-Hodgkin's lymphoma presented with massive ascites, peritoneal involvement and elevated CA-125 level**
Doventas A., YILDIZ İ., TOPTAŞ T., Baslar Z., Bilici A., ERDİNÇLER Ü. D.
JOURNAL OF BUON, vol.14, no.2, pp.324-325, 2009 (SCI-Expanded)

Articles Published in Other Journals

- I. **Impact of Professional Seniority on Total Neoadjuvant Treatment Approach for Locally Advanced Rectal Cancer**
Şenocak Taşçı E., AYTAÇ E., Ajredini M., Mutlu A. U., YILDIZ İ., OZER L.
Journal of Oncological Science, vol.9, no.2, pp.89-96, 2023 (Scopus)
- II. **Liver and Pancreatic Injury in Response to ALK Inhibitors in a Patient with Primary Signet Ring Cell Carcinoma of the Lung: A Case Report**
YILDIZ İ.
CASE REPORTS IN ONCOLOGY, vol.14, no.1, pp.107-111, 2021 (Peer-Reviewed Journal)
- III. **The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients**
Yıldız İ.
JOURNAL of ONCOLOGICAL SCIENCES, vol.4, no.1, pp.60-61, 2018 (Peer-Reviewed Journal)
- IV. **Alteration of thyroid functions in patients with renal cell carcinoma treated with tyrosine kinaseinhibitors Turkish population study**
BİLİR C., YILDIZ İ., BİLİCİ A., UÇAR M., BERK V., YILDIZ Y., YAZICI O., İMAMOĞLU G. İ., KARADURMUŞ N., PİLANCI K. N., et al.
Journal of Human Rhythm, vol.2, no.4, pp.144-148, 2016 (Peer-Reviewed Journal)
- V. **Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients**
Ordu C., Pilanci K. N., Avci N., YILDIZ İ., Alco G., Demirhan O., Koksall U. I., Elbuken F., Tecimer C., Demir G.
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, vol.20, no.2, pp.147-152, 2016 (ESCI)
- VI. **Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study**
Bayoglu I. V., Yildiz İ., Varol U., Cokmert S., Alacacioglu A., Kucukzeybek Y., Akyol M., Demir L., Dirican A., Tarhan O.
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, vol.19, no.5, pp.385-390, 2015 (ESCI)
- VII. **Assessment of the Quality of Life in Turkish Breast Cancer Patients**
Yildiz İ., Varol U., Alacacioglu A.
JOURNAL OF BREAST HEALTH, vol.10, no.4, pp.216-221, 2014 (ESCI)

- VIII. **Survival Analysis of Triple Negative and Her2 Positive Breast Cancer Patients: Single Center Report**
Varol U., ÇAKAR B., Yildiz İ., TUNAKAN DALGIÇ C., ÖZİŞİK H., Ozisik M., Karaca B., KARABULUT B., Uslu R.
JOURNAL OF BREAST HEALTH, vol.10, no.1, pp.42-46, 2014 (Peer-Reviewed Journal)
- IX. **A case of non-Hodgkin lymphoma coexisting with both hepatitis B and tuberculosis**
Yildiz İ., Varol U., Varol Y., BAŞARAN M.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.29, no.2, pp.53-56, 2014 (ESCI)
- X. **Isolated Liver Metastasis of Sacrococcygeal Chordoma: Case Report and Review of the Literature**
Akyol M., Varol U., Yildiz İ., Bayoglu I. V., Yildiz Y., Demir L., Dirican A., Can A., Cokmert S., Oztop M. T., et al.
CASE REPORTS IN ONCOLOGICAL MEDICINE, vol.2014, 2014 (ESCI)
- XI. **Intolerance to sunitinib treatment in hemodialysis patients with metastatic renal cell carcinoma.**
YILDIZ İ., Sen F., Kilic L., Ciftci R., BAŞARAN M.
Korean journal of urology, vol.55, no.1, pp.74-6, 2014 (Peer-Reviewed Journal)
- XII. **Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival.**
TAŞ F., Sen F., Keskin S., Kilic L., YILDIZ İ.
Molecular and clinical oncology, vol.1, no.4, pp.788-792, 2013 (Peer-Reviewed Journal)
- XIII. **Primary Burkitt's Lymphoma Presenting as a Rapidly Growing Thyroid Mass**
YILDIZ İ., Sen F., Toz B., Kilic L., Agan M., BAŞARAN M.
CASE REPORTS IN ONCOLOGY, vol.5, no.2, pp.388-393, 2012 (ESCI)

Books & Book Chapters

- I. **Adjuvant Systemic Therapy: Endocrine Therapy**
Yıldız İ.
in: Breast Disease, Adnan Aydiner Abdullah İğci Atilla Soran, Editor, Springer-Verlag , Zürich, pp.103-127, 2019
- II. **Adjuvant Endocrine Therapy for Breast Cancer**
Yıldız İ., Aydiner A.
in: Breast Cancer : A Guide to Clinical Practice, Adnan Aydiner Abdullah İğci Atilla Soran, Editor, Springer, London/Berlin , London, pp.413-432, 2019
- III. **Adjuvant Endocrine Therapy**
Yıldız İ.
in: Breast Disease: Management and Therapies, Adnan Aydiner, Atilla Soran, Abdullah İğci, Editor, Springer, London/Berlin , Basel, pp.99-130, 2016

Refereed Congress / Symposium Publications in Proceedings

- I. **The prognostic impact of intramural invasion in patients undergoing surgery for non-metastatic colon cancer.**
Ozer L., Tasci E. S., Mutlu A. U., Piyade B., Ramoglu N., Ajredini M., Gurleyik D., Cecen R., Dincer S. N., Musevitoglu T., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 June 2022
- II. **The professional seniority affects the clinical application of total neoadjuvant therapy for locally advanced rectal cancer.**
Tasci E. S., AYTAÇ E., Ajredini M., Mutlu A. U., Yildiz İ., Ozer L.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 June 2022
- III. **Clinicopathological and prognostic significance of microsatellit instability (MSI) status and PDI-1 expression in Turkish patients with gastric cancer.**
Yildiz İ., Bahsi S., Erdamar S., Goksel S., Demir G., Er O., Baca B., Karahasanoolu T., Hamzaoglu İ. H., Arican A., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04

June 2019, vol.37

- IV. **Sexual satisfaction, anxiety, depression and quality of life among Turkish gynecological cancer patients**
Yildiz Y., Akyol M., Alacacioglu A., Kucukzeybek Y., Asik N., Taskaynatan H., Varol U., Yildiz İ., Oflazoglu U., Salman T., et al.
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Denmark, 7 - 11 October 2016, vol.27
- V. **Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib**
Neiman V., Keizman D., Sarid D., Lee J., Sella A., Gottfried M., Hammers H., Eisenberger M., Carducci M., Sinibaldi V., et al.
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Denmark, 7 - 11 October 2016, vol.27
- VI. **Thrombin activatable fibrinolysis inhibitor, tissue factor pathway inhibitor, and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer.**
Salman T., Bilici A., Arslan C., Varol U., Yildiz İ., Akyol M., Yildiz Y., Kucukzeybek Y., Alacacioglu A., Yilmaz U.
Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 21 - 23 January 2016, vol.34
- VII. **Evaluation of c-kit (CD 117) expression as a prognostic factor in testicular germ cell tumors: An Izmir Oncology Group (IZOG) study.**
Salman T., Yildiz E., Yildiz İ., Yavuzer D., Unlu M., Varol U., Akyol M., Yildiz Y., Bayoglu V., Kucukzeybek Y., et al.
Genitourinary Cancers Symposium, San-Francisco, Costa Rica, 7 - 09 January 2016, vol.34
- VIII. **The effects of adjuvant endocrine treatment on the serum leptin, adiponectin and body composition in patients with breast cancer [Izmir Oncology Group (IZOG) Study]**
Akyol M., Demir L., Alacacioglu A., Ellidiokuz H., Kucukzeybekl Y., Yildiz Y., Bayoglu V., Yildiz İ., Salman T., Varol U., et al.
European Cancer Congress, Vienna, Austria, 01 January 2015, vol.51
- IX. **First-line cisplatin plus bolus 5-Fluorouracil combination in patients with locally advanced and metastatic esophageal cancer**
Akyol M., Kucukzeybek Y., Varol U., Yildiz İ., Cokmert S., Bayoglu I. V., Yildiz Y., Demir L., Can A., Dirican A., et al.
ESMO 17th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 1 - 04 July 2015, vol.26
- X. **Can basal neutrophil/lymphocytes ratio predict clinical outcome of melanoma patients?**
Bayoglu I. V., Kurtel G., Alacacioglu A., Varim C., Yildiz İ., Kucukzeybek Y., Dirican A., Demir L., Yildiz Y., Akyol M., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XI. **Patients (pts) with metastatic chromophobe renal cell carcinoma (mchRCC) treated with sunitinib (Su) therapy (tx): Analysis of an international database regarding outcome and comparison to clear cell histology (mccRCC)**
Yildiz İ., Sarid D., Lee J., Chish A., Sella A., Gottfried M., Hammers H. J., Eisenberger M. A., Carducci M. A., Sinibaldi V. J., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XII. **Patients with metastatic chromophobe renal cell carcinoma treated with sunitinib therapy: Analysis of an international database regarding outcome and comparison to clear cell histology (mccRCC).**
Keizman D., Sarid D., Lee J., Gottfried M., Maimon N., Hammers H. J., Eisenberger M. A., Carducci M. A., Sinibaldi V. J., Neiman V., et al.
Genitourinary Cancers Symposium, Florida, United States Of America, 26 - 28 February 2015, vol.33
- XIII. **Clinical significance of serum macrophage migration inhibitory factor (MIF) level in breast cancer.**
Ciftci R., TAŞ F., Aksit E., VATANSEVER S., KARABULUT S., Sen F., Yildiz İ., Keskin S., Bozbey H. U., Kilic L., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 30 May - 03 June 2014, vol.32

- XIV. **Sunitinib in patients with metastatic non-clear renal cell carcinoma: A multicentric retrospective Turkish Oncology Group (TOG) trial.**
Yildiz İ., EKENEL M., Altman T., Kocar M., Uysal M., Kanitez M., Bayoglu V., Varol U., Tural D., Avci N., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XV. **Clinical significance of serum protein and mRNA level of insulin-like growth factor-1 (IGF-1) in patients with hepatocellular carcinoma**
KARABULUT S., Aykan N. F., Yildiz İ., Kilic L., Sen F., VATANSEVER S.
Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 16 - 18 January 2014, vol.32
- XVI. **Coagulation assays in breast cancer: Correlation of plasma D-dimer with tumor load and invasiveness in breast cancer patients.**
KARABULUT S., Kilic L., Ciftci R., Yildiz İ., Sen F., Keskin S., TAŞTEKİN D., TAŞ F.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XVII. **Effect of increased body mass index on time to tumor progression in metastatic unresectable colorectal cancer patients treated with bevacizumab-based therapy**
Yildiz İ., Sen F., Kilic L., Keskin S., Ciftci R., EKENEL M., Aykan N. F.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XVIII. **Comparison of mucosal and cutaneous melanoma in the head and neck region: Different clinical features and similar outcomes.**
Ciftci R., Keskin S., KARABULUT S., Yildiz İ., Kilic L., Sen F., TAŞTEKİN D., TAŞ F.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XIX. **Is there any prognostic importance of pretreatment serum M30 and serum M65 levels on progression-free survival of patients with metastatic renal cell carcinoma treated with first-line sunitinib?**
BAŞARAN M., Yildiz İ., Sen F., Kilic L., Keskin S., Darendeliler E., Bavbek S. E.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XX. **Imatinib meylate response in gastrointestinal stromal tumors Experience of Cerrahpasa Medical Faculty**
YILDIZ İ., MANDEL N. K., DEMİR O. G., ÖZGÜROĞLU M., TOPTAŞ T., BÜYÜKÜNAL E., SERDENGEÇTİ S.
31st ESMO Congress, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.164
- XXI. **Erdheim-Chester disease: Report of a case**
Yildiz İ., Mandel N. M., Dervisoglu S., Toptas T.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.210
- XXII. **Imatinib mesylate response in Gastrointestinal Stromal Tumors: Experience of cerrahpasa medical faculty**
Yildiz İ., Mandel N. M., Demir G., Ozguroglu M., Toptas T., Buyukunal E., Serdengecti S.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.164

Supported Projects

Yıldız İ., Project Supported by Private Organizations in Other Countries, Yüksek Riskli Evre II-IV Melanom Bulunan Gönüllülerde Adjuvan Plasebo Artı Pembrolizumaba Kıyasla Adjuvan V940 (mRNA-4157) Artı Pembrolizumabın Değerlendirildiği Randomize, Çift Kör, Plasebo ve Aktif Komparatör Kontrollü Faz 3 Klinik Çalışma”, 2023 - 2025
Yıldız İ., Project Supported by Private Organizations in Other Countries, A Phase 3, Randomized Study to Evaluate the

Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma, 2023 - 2025

Memberships / Tasks in Scientific Organizations

ASCO, Principal Member, 2020 - Continues, United States Of America

ESMO, Principal Member, 2019 - Continues, Switzerland

Türk Tibbi Onkoloji Derneği, Principal Member, 2010 - Continues, Turkey

Scientific Refereeing

ANNALS OF ONCOLOGY, SCI Journal, July 2015

Metrics

Publication: 125

Citation (WoS): 628

Citation (Scopus): 625

H-Index (WoS): 13

H-Index (Scopus): 14

Congress and Symposium Activities

10. Türk Tibbi Onkoloji Kongresi, Invited Speaker, Antalya, Turkey, 2023

Hedef Kanser, Panelists, Girne, Cyprus (Kktc), 2023

AVOD Onkoloji Günleri, Invited Speaker, Eskişehir, Turkey, 2023

9. Türk Tibbi Onkoloji Kongresi, Moderator, Girne, Cyprus (Kktc), 2022

Hedef Kanser 2022, Panelists, Girne, Cyprus (Kktc), 2022

8. Türk Tibbi Onkoloji Kongresi, Moderator, Antalya, Turkey, 2021

Awards

Yıldız İ., Sunitinib ile tedavi edilen metastatik kanserli hastalarda koroner akım rezervinin değerlendirilmesi, Türk Tibbi Onkoloji Derneği, June 2012

Yıldız İ., 2012 YILI AKADEMİK ÇALIŞMA ÖDÜLÜ, İstanbul Üniversitesi Onkoloji Enstitüsü, April 2012